Actavis Realigns OTC, Rx Businesses To Increase Efficiency
This article was originally published in The Tan Sheet
Executive Summary
The global specialty brand and generics company is simplifying its structure and combining units to make communication and decisions across the business more effective as it strives to grow organically.
You may also be interested in...
In Brief
Watson adds Actavis for $5.6 bil.; Recordati buys OTCs in Germany; DoJ weighs in on Plan B case; NARC rebranded as ASRC; Korean lawmakers miss another chance on OTC bill; more news In Brief.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.